Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425787 | 0.81 | DPP4 (0.41) | DPP4 | |
| SCHEMBL28571189 | 0.80 | DPP4 (0.32) | DPP4 | |
| SCHEMBL2816769 | 0.78 | DPP4 (0.39) | DPP4 | |
| SCHEMBL7939966 | 0.78 | POLB (0.36) | — | |
| SCHEMBL82678 | 0.75 | DPP4 (0.33) | DPP4 | |
| SCHEMBL21356928 | 0.75 | DPP4 (0.33) | DPP4 | |
| SCHEMBL81506 | 0.75 | DPP4 (0.33) | DPP4 | |
| SCHEMBL19138932 | 0.73 | TP53 (0.36) | — | |
| SCHEMBL15519632 | 0.72 | TSHR (0.36) | DPP4 | |
| SCHEMBL5420439 | 0.72 | DPP4 (0.34) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487096-B2 | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors | INCYTE CORPORATION (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | INCYTE CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212967-A1 | IMIDAZO[1,2-B][1,2,4]TRIAZINES AS C-MET INHIBITORS | MET, RET, ERBB2 | DPP4 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.